RxDoctor Payments Data

Vikas Pilly, MD

Interventional Pain Medicine · Williamsville, NYNPI 1841302403

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $14,875 of the $19,136 with a category attached, or 77.7%. Caerus Corp. accounts for 77.7% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2020 at $15,008 and has fallen 97.7% since, to $348 in 2025.

$19,136in general payments, 2019–2025

Across 132 payments — averaging $144.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Caerus Corp.$15K
  • Boston Scientific$1K
  • Abbott$736
  • Averitas Pharma Inc.$574
  • Nevro Corp.$371
  • Curonix LLC$365
  • plus $982 from 19 others

What the payments were for

  • Consulting fees$14,87578%
  • Travel & lodging$2151%
  • Food & beverage$4,04621%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,136 in reported general payments places this provider in the 85th percentile of 132 interventional pain medicine providers in New York.

See all interventional pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$34,963
Medicare patients
58
Services billed
2,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QutenzaCapsaicin/Skin Cleanser20$75,688
Nucynta ErTapentadol Hcl13$8,060
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen101$4,439
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen153$3,782
Gabapentin234$2,928
Lidocaine12$2,081
Naloxone Hcl27$1,955
Tramadol Hcl ErTramadol Hcl11$1,795
Pregabalin68$1,352
Oxymorphone Hcl ErOxymorphone Hcl13$858
Baclofen26$404
Cyclobenzaprine Hcl33$362
Tizanidine Hcl14$346
Nortriptyline Hcl17$258
Morphine Sulfate ErMorphine Sulfate11$240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er$55$8,06013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 132 interventional pain medicine providers in New York.

Other interventional pain medicine in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →